GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (ASX:CUV) » Definitions » Profitability Rank

Clinuvel Pharmaceuticals (ASX:CUV) Profitability Rank : 9 (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Clinuvel Pharmaceuticals Profitability Rank?

Clinuvel Pharmaceuticals has the Profitability Rank of 9. It has a higher profitability and may stay that way.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Clinuvel Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 was 41.40%. As of today, Clinuvel Pharmaceuticals's Piotroski F-Score is 7.


Competitive Comparison of Clinuvel Pharmaceuticals's Profitability Rank

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinuvel Pharmaceuticals's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Profitability Rank falls into.



Clinuvel Pharmaceuticals Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Clinuvel Pharmaceuticals has the Profitability Rank of 9. It has a higher profitability and may stay that way.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Clinuvel Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=13.353 / 32.257
=41.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Clinuvel Pharmaceuticals has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Good Sign:

Clinuvel Pharmaceuticals Ltd operating margin is expanding. Margin expansion is usually a good sign.

4. Consistency of the profitability

5. Predictability Rank


Clinuvel Pharmaceuticals Profitability Rank Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals (ASX:CUV) Business Description

Traded in Other Exchanges
Address
535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (ASX:CUV) Headlines

No Headlines